ATE208634T1 - Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc - Google Patents

Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc

Info

Publication number
ATE208634T1
ATE208634T1 AT94906558T AT94906558T ATE208634T1 AT E208634 T1 ATE208634 T1 AT E208634T1 AT 94906558 T AT94906558 T AT 94906558T AT 94906558 T AT94906558 T AT 94906558T AT E208634 T1 ATE208634 T1 AT E208634T1
Authority
AT
Austria
Prior art keywords
cell proliferation
smooth muscle
muscle cell
pct
myc
Prior art date
Application number
AT94906558T
Other languages
English (en)
Inventor
Andrew Zalewski
Yi Shi
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE208634T1 publication Critical patent/ATE208634T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94906558T 1993-01-07 1994-01-07 Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc ATE208634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US479993A 1993-01-07 1993-01-07
PCT/US1994/000265 WO1994015646A1 (en) 1993-01-07 1994-01-07 Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells

Publications (1)

Publication Number Publication Date
ATE208634T1 true ATE208634T1 (de) 2001-11-15

Family

ID=21712588

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94906558T ATE208634T1 (de) 1993-01-07 1994-01-07 Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc

Country Status (16)

Country Link
US (1) US6159946A (de)
EP (1) EP0690726B1 (de)
JP (1) JPH08505397A (de)
KR (1) KR100316205B1 (de)
CN (1) CN1119830A (de)
AT (1) ATE208634T1 (de)
AU (1) AU685080B2 (de)
BR (1) BR9405707A (de)
CA (1) CA2153158A1 (de)
CZ (1) CZ172395A3 (de)
DE (1) DE69429087T2 (de)
DK (1) DK0690726T3 (de)
ES (1) ES2167358T3 (de)
HU (1) HU220969B1 (de)
PT (1) PT690726E (de)
WO (1) WO1994015646A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2153158A1 (en) * 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
EP0732940B1 (de) * 1993-10-15 2001-12-19 Thomas Jefferson University Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
AU4923696A (en) * 1995-02-10 1996-08-27 Nexstar Pharmaceuticals, Inc. Lipid constructs for cytoplasmic delivery of agents
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6265389B1 (en) * 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997014440A1 (en) * 1995-10-19 1997-04-24 Johnson & Johnson Interventional Systems Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
KR20010072475A (ko) * 1998-08-13 2001-07-31 추후제출 재발협착증을 치료하기 위한 ｄｎａ자임 및 치료 방법
US7094765B1 (en) * 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
JP2002535015A (ja) * 1999-01-29 2002-10-22 エイブイアイ バイオファーマ， インコーポレイテッド 標的ｒｎａを検出するための非侵襲性方法
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
WO2001023550A2 (en) 1999-09-29 2001-04-05 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
JP5000826B2 (ja) * 2000-01-24 2012-08-15 バイオコンパテイブルズ・ユーケイ・リミテツド 被覆されたインプラント
WO2001072203A2 (en) * 2000-03-24 2001-10-04 Temple University-Of The Commonwealth System Of Higher Education Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents
WO2002034908A2 (en) * 2000-10-23 2002-05-02 Mermaid Pharmaceuticals Gmbh Method for temporally controlling antisense-mediated gene inactivation
CA2447052A1 (en) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Combined approach to treatment of cancer using a c-myc antisense oligomer
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US7241581B2 (en) * 2002-08-16 2007-07-10 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
US7407672B2 (en) * 2002-11-04 2008-08-05 National Heart Center Composition derived from biological materials and method of use and preparation
DK1569695T3 (da) 2002-11-13 2013-08-05 Genzyme Corp Antisense-modulering af apolipoprotein-b-ekspression
WO2004044181A2 (en) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
ATE479763T1 (de) * 2003-04-29 2010-09-15 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
KR100818047B1 (ko) 2005-11-25 2008-03-31 한국원자력연구원 평활근-22α의 활성을 억제하여 암세포의 사멸을 촉진하는방법 및 평활근-22α의 활성 억제제를 유효성분으로포함하는 항암제
AU2008271050B2 (en) * 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP6091752B2 (ja) * 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP5981850B2 (ja) * 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
US9222088B2 (en) * 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9228189B2 (en) * 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3302489A4 (de) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
SE462364B (sv) * 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
HU217036B (hu) * 1990-08-03 1999-11-29 Sanofi Eljárás génexpresszió gátlására alkalmas vegyületek előállítására
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5122048A (en) * 1990-09-24 1992-06-16 Exxon Chemical Patents Inc. Charging apparatus for meltblown webs
EP0558697A1 (de) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5756476A (en) * 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5961094A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
AU6080294A (en) * 1992-12-31 1994-08-15 Texas Biotechnology Corporation Antisense molecules directed against genes of the (raf) oncogene family
CA2153158A1 (en) * 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
CA2164632A1 (en) * 1993-06-11 1994-12-22 John P. Cooke Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
EP0732940B1 (de) * 1993-10-15 2001-12-19 Thomas Jefferson University Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind

Also Published As

Publication number Publication date
CN1119830A (zh) 1996-04-03
KR960700076A (ko) 1996-01-19
DE69429087T2 (de) 2002-07-11
HU220969B1 (hu) 2002-07-29
US6159946A (en) 2000-12-12
JPH08505397A (ja) 1996-06-11
HU9502061D0 (en) 1995-09-28
WO1994015646A1 (en) 1994-07-21
EP0690726A4 (de) 1998-10-07
ES2167358T3 (es) 2002-05-16
HUT71937A (en) 1996-02-28
EP0690726B1 (de) 2001-11-14
DK0690726T3 (da) 2002-03-11
DE69429087D1 (de) 2001-12-20
CZ172395A3 (en) 1996-03-13
KR100316205B1 (ko) 2002-04-24
AU6023594A (en) 1994-08-15
BR9405707A (pt) 1996-08-06
AU685080B2 (en) 1998-01-15
CA2153158A1 (en) 1994-07-21
EP0690726A1 (de) 1996-01-10
PT690726E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
ATE208634T1 (de) Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
ATE278399T1 (de) Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
SI0882021T1 (en) New phenanthridines
MX9801093A (es) Inhibidores de la proteinasa c para el tratamiento de enfermedades relacionadas con la sobreproduccion de colagena.
DE69424537T2 (de) Therapeutischer wirkstoff zur behandlung von melanomen
EP0871496A4 (de)
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
HRP931515A2 (en) Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorbtion inhibitor
HK1029052A1 (en) Inhibition of raf kinase using substituted heterocyclic ureas.
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
ATE321452T1 (de) Tetracycline verbindungen zur behandlung von spezifischen krebsarten
AP9701007A0 (en) Substituted azetidin-2-ones for treatment of atherosclerosis.
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
DE69232629D1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DK0674716T3 (da) Retrovirale vektorer til behandling af tumorer og cellelinier, der indeholder dem
MX9702035A (es) Inhibidores de 5-alfa reductasa.
DE69524623T2 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69319590T2 (de) Melamine derivate zur verwendung in der behandlung von krebs
AU5818394A (en) Use of prodelphinidines for treating arthrosis
DE69510545T2 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
GB9920502D0 (en) Portable terminal
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee